Effect of Channa striata Extract Supplementation on Febrile Neutropenia in Acute Myeloid Leukemia Patients Undergoing Chemotherapy: A Randomized Controlled Study

斑鳢提取物补充剂对接受化疗的急性髓系白血病患者发热性中性粒细胞减少症的影响:一项随机对照研究

阅读:2

Abstract

INTRODUCTION: Febrile neutropenia is one of the most serious complications in patients with hematological malignancies and chemotherapy. Channa striata is a freshwater fish belonging to the family Channidae. This study aims to determine whether the administration of channa striata extract can increase neutrophil count, neutrophil function and prevent incidence of febrile neutropenia in acute myeloid leukemia (AML) patients receiving chemotherapy. METHOD: A randomized, single-blind, controlled study compared a standard nutrition from hospital with a channa striata extract-supplemented per oral containing 6 grams of channa striata extract in patients with acute myeloid leukemia undergoing intensive chemotherapy. To analyze the effects of channa striata extract on function of neutrophil, Interleukin (IL)-6 and nitric oxide (NO) levels which are the result of neutrophil phagocytosis were assessed. RESULTS: A total of 32 AML patients were randomized to receive per oral supplementation of channa striata extract (6 g/day) or nutrition from the hospital during intensive chemotherapy and after chemotherapy. The median onset of neutropenia was 6.1 + 3.37 in the channa striata extract group and 8.8 + 4.59 in the control group (p=0.109). The median duration of neutropenia was 12.8 + 6.20 d in the channa striata group and 17.2 + 11.06 d in the control group (p=0.281), whereas the incidence of febrile neutropenia were 85,7% in the channa striata extract group and 43,8% in the control group with median duration of neutropenic fever were 5.7 + 3.56 and 4.7 + 4.57, respectively. The chi-square test in the IL-6 delta category showed a tendency for IL-6 levels to rise in 61.5% of subjects in the Channa striata group compared to the control group (p=0.182). CONCLUSION: Channa striata extract supplementation did not influence neutropenia onset, duration, neutrophil function, or neutropenic fever in AML patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。